NOBODY DOES PROTEINS LIKE WE DO
The biotech industry develops therapies specifically tailored for people and their conditions. Why should pets be any different?
Using our Ambifect® Fc-fusion protein platform, Akston generates novel protein therapeutics that deliver customized, long-acting agents for a wide variety of diseases.
In our pipeline:
TARGETED PRECISION PROTEINS & IMMUNO-ENHANCING PROTEINS
Targeted precision proteins
Therapeutic proteins that last longer for
obesity and cancer
- Once-a-week vs twice-a-day
- Better coverage = better outcomes
- Lower overall cost of care
Immuno-enhancing proteins
Convenient, low-cost alternatives to monoclonal antibodies (mAbs) for chronic pain, dermatitis, and cancer
- Twice-a-year vs once-a-month
- 50x less material than mAbs
- Single product for all weight classes
| Laboratory | Target Animal | Target Disease | Regulatory Submission | Market | |
|---|---|---|---|---|---|
|
AKS-701d
CANINE ONCOLOGY
Anti-PD-L1 Monoclonal antibody |
|||||
|
AKS-562c
FELINE OBESITY
FcRn recycled GLP-1 for once-a-week dosing |
|||||
|
CONFIDENTIAL
CANINE OBESITY
Brown adipose tissue recruitment |
|||||
|
AKS-197d
CANINE ONCOLOGY
Insulin growth factor receptor downregulation |
|||||
|
AKS-427c
FELINE ONCOLOGY
Insulin growth factor receptor downregulation |
|||||
|
AKS-548d
CANINE CHRONIC PAIN
Anti-NGF Ambifect |
|||||
|
AKS-637d
CANINE ATOPIC DERMATITIS
Anti-IL-31 Ambifect |
|||||
|
AKS-616d
CANINE ONCOLOGY
Anti-PD-L1 Ambifect |
SPOTLIGHT: AKS-562c
FELINE OBESITY
FcRn recycled GLP-1 for
once-a-week dosing
SPOTLIGHT: AKS-548d
CANINE CHRONIC PAIN
NGF immunotherapy
We move fast. Want to
keep up?
KEEP UP WITH AKSTON
Get the latest Akston news tailored to your interests.